The University of Oxford confirmed that the Covid-19 vaccine it’s developing with AstraZeneca Plc produced strong immune responses in older adults in an early study, with pivotal findings from the final phase of trials expected in the coming weeks. The results of Oxford’s phase 2 study show that the vaccine is better tolerated in older people and produces a similar immune response in old and young adults. That follows findings in older participants unveiled last month and data in July that showed the vaccine generated robust immune responses in adults ages 18 to 55. “Inducing robust immune responses in older adults has been a long-standing challenge," Angela Minassian, an investigator at Oxford, wrote in a statement. “To show this vaccine technology is able to induce these responses -- in the age group most at risk from severe Covid-19 disease -- offers hope that vaccine efficacy will be similar in younger and older adults."

Source: Mint November 19, 2020 06:56 UTC